Literature DB >> 19923262

Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.

Carol McDonald1, Claudio Elgueta Karstegl, Paul Kellam, Paul J Farrell.   

Abstract

Ten novel mutations were introduced into the Zp promoter to test the role of sequences outside the established transcription factor-binding sites in Epstein-Barr virus (EBV) reactivation. Most of these had only small effects, but mutations in the ZID site were shown to reduce Zp activity strongly at early times after induction by anti-immunoglobulin (anti-Ig). The binding of MEF2 transcription factor to ZID was characterized in detail and linked functionally to Zp promoter activity. The presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp. Silencing of Zp during latency is thought to be primarily a consequence of a repressive chromatin structure on Zp, and this aspect of Zp regulation can be observed in the Akata genome through protection of Zp from activation by BZLF1 in the absence of signalling from the B-cell receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923262     DOI: 10.1099/vir.0.017277-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.

Authors:  Takayuki Murata; Yohei Narita; Atsuko Sugimoto; Daisuke Kawashima; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

2.  Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency.

Authors:  Nicholas J Homa; Raul Salinas; Eleonora Forte; Timothy J Robinson; Mariano A Garcia-Blanco; Micah A Luftig
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.

Authors:  Courtney M Shirley; Jianmeng Chen; Meir Shamay; Huili Li; Cynthia A Zahnow; S Diane Hayward; Richard F Ambinder
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

4.  Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.

Authors:  Pei-Fang Tsai; Sue-Jane Lin; Pei-Lun Weng; Shu-Chun Tsai; Jiun-Han Lin; Ya-Ching Chou; Ching-Hwa Tsai
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

5.  X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein-Barr virus in co-infected primary effusion lymphoma.

Authors:  Imogen Yi-Chun Lai; Paul J Farrell; Paul Kellam
Journal:  J Gen Virol       Date:  2010-10-27       Impact factor: 3.891

6.  Myocyte enhancer factor (MEF)-2 plays essential roles in T-cell transformation associated with HTLV-1 infection by stabilizing complex between Tax and CREB.

Authors:  Pooja Jain; Alfonso Lavorgna; Mohit Sehgal; Linlin Gao; Rashida Ginwala; Divya Sagar; Edward W Harhaj; Zafar K Khan
Journal:  Retrovirology       Date:  2015-02-27       Impact factor: 4.602

Review 7.  Regulation of the Macroautophagic Machinery, Cellular Differentiation, and Immune Responses by Human Oncogenic γ-Herpesviruses.

Authors:  Christian Münz
Journal:  Viruses       Date:  2021-05-08       Impact factor: 5.048

Review 8.  Roles of Lytic Viral Replication and Co-Infections in the Oncogenesis and Immune Control of the Epstein-Barr Virus.

Authors:  Yun Deng; Christian Münz
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.